(ARGX) – StreetInsider.com Reports
-
argenx SE (ARGX) PT Raised to $408 at Scotiabank
-
Guggenheim reiterates Buy rating on Tourmaline Bio (TRML), "news is likely to increase investors' perceived risk"
-
Roche falls, Argenx (ARGX) gains after Chugai's Enspryng drug for myasthenia gravis fails
-
argenx SE (ARGX:BB) (ARGX) PT Raised to EUR477 at Morgan Stanley
-
argenx SE (ARGX) PT Raised to $515 at Morgan Stanley
-
argenx SE (ARGX) PT Raised to $440 at Truist Securities on upcoming PDUFA, and 'positive read-through from nipocalimab'
-
argenx SE (ARGX:BB) (ARGX) PT Lowered to EUR490 at JPMorgan
-
argenx SE (ARGX) PT Raised to $402 at Scotiabank
-
argenx SE (ARGX) PT Lowered to $490 at Baird
-
argenx SE (ARGX) PT Raised to $471 at JMP Securities
-
argenx (ARGX) Misses Q4 EPS by 35c
-
argenx SE (ARGX) PT Raised to $478 at Wells Fargo
-
argenx (ARGX) Announces FDA Acceptance of sBLA and Priority Review for VYVGART Hytrulo
-
Wolfe Research begins coverage on biotech, names Alpine Immune Sciences as Top Pick
-
Wolfe Research Starts argenx SE (ARGX) at Peerperform
-
argenx SE (ARGX:BB) (ARGX) PT Raised to EUR360 at Barclays
-
argenx SE (ARGX) PT Raised to $522 at Piper Sandler
-
argenx SE (ARGX) PT Raised to $518 at Piper Sandler
-
argenx (ARGX) Announces Approval of VYVDURA in Japan
-
argenx SE (ARGX) PT Raised to $472 at Wells Fargo
-
argenx SE (ARGX) PT Raised to $499 at Jefferies
-
argenx (ARGX) Highlights 2024 Strategic Priorities
-
argenx SE (ARGX:BB) (ARGX) PT Lowered to EUR410 at UBS
-
argenx SE (ARGX:BB) (ARGX) PT Lowered to EUR407 at Goldman Sachs
-
argenx SE (ARGX:BB) (ARGX) PT Lowered to EUR552 at BofA Securities
-
argenx SE (ARGX:BB) (ARGX) PT Lowered to EUR465 at Morgan Stanley
-
argenx SE (ARGX:BB) (ARGX) PT Lowered to EUR510 at Morgan Stanley
-
argenx SE (ARGX) PT Lowered to $510 at Morgan Stanley
-
Morgan Stanley is bullish on this beaten-down biotech stock
-
argenx SE (ARGX) PT Lowered to $446 at Goldman Sachs
-
argenx SE (ARGX) PT Lowered to $514 at TD Cowen
-
argenx SE (ARGX) PT Lowered to $515 at Piper Sandler
-
argenx SE (ARGX) PT Lowered to $346 at Scotiabank
-
argenx SE (ARGX) PT Lowered to $451 at H.C. Wainwright
-
argenx SE (ARGX) PT Lowered to $430 at Guggenheim
-
argenx SE (ARGX) PT Lowered to $470 at Wells Fargo
-
argenx SE (ARGX) PT Lowered to $435 at Evercore ISI
-
Barclays Downgrades argenx SE (ARGX:BB) (ARGX) to Equalweight
-
argenx SE (ARGX) PT Lowered to $370 at Truist Securities, 'If ADDRESS Results Hold It'd Be A Breakthrough For PV But Not One That Would Benefit ARGX'
-
These 6 stocks are new Top Picks at Jefferies
-
William Blair Downgrades argenx SE (ARGX) to Market Perform
-
Tourmaline Bio (TRML) is 'a big winner' of Argenx (ARGX) failure - Truist
-
Immunovant (IMVT) Trades Lower in Sympathy with argenx (ARGX)
-
argenx SE (ARGX) Defended at Stifel
-
Deutsche Bank Issues Mea Culpa, Downgrades argenx SE (ARGX:BB) (ARGX) to Hold
-
argenx (ARGX) Reports ADDRESS Study of Efgartigimod SC Did Not Achieve Statistical Significance
-
argenx SE (ARGX) PT Raised to $560 at Stifel
-
Jefferies updates its Franchise Picks list
-
argenx SE (ARGX) PT Raised to $641 at TD Cowen; Named Best 2024 Idea
-
argenx SE (ARGX) PT Lowered to $560 at JPMorgan
Back to ARGX Stock Lookup